Manlio Loconte
Anatomic Pathology & Clinical Pathology · Boston, MANPI 1114984820
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $112,133 of the $112,233 with a category attached, or 99.9%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $42,862, more than ten times the $23 reported in 2019. Among anatomic pathology & clinical pathology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 36 payments — averaging $3117.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$112K
- Orexo US, Inc.$38
What the payments were for
- Consulting fees$112,133100%
- Travel & lodging$620%
- Food & beverage$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $112,195 |
| Orexo US, Inc. | 3 | $38 |
How this compares
$112,233 in reported general payments places this provider in the 95th percentile of 196 anatomic pathology & clinical pathology providers in Massachusetts.
See all anatomic pathology & clinical pathology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 68 | $23,598 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 165 | $14,453 |
| Buprenorphine Hcl | 17 | $159 |
Paid to pharmacies, not to this prescriber.
Other anatomic pathology & clinical pathology in Boston
- Jason BaronBoston$336K
- Lida HaririBoston$47K
- Omer YilmazBoston$28K
- Lance TruongBoston$25K
- John BrandaBoston$23K
- Vikram DeshpandeBoston$21K
- Nancy MillerBoston$15K
- Lynne UhlBoston$14K
- Scott RodigBoston$14K
- Kyle DevinsBoston$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.